Begin main content

Reports

We found 4919 result(s)

Memantine for treatment of moderate to severe Alzheimer's disease

Published on: March 11, 2005
Result type: Reports

Summary Health Canada has issued a Notice of Compliance with conditions (NOC/c) for memantine in the treatment of moderate to severe Alzheimer's disease (AD). The evidence of relative benefit and harm from memantine in this population derives from two randomized controlled trials (RCT) of 24 to 28 weeks duration, in a total of 656 patients; and ...

Tags

Alzheimer Disease, Alzheimer's Disease, Memantine, Ebixa, Cholinesterase Inhibitors, Chemotherapy, Drug Therapy, NMDA, Alzheimer, Maladie d'Alzheimer, Anticholinestérasiques, Donepezil, Adjuvant, Adjunctive therapy, Chimiothérapie

Mycophenolate sodium (Myfortic)

Last Updated: March 3, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Mycophenolate sodium
Indications: Organ rejection in allogeneic renal transplants, Prophylaxis

  • Brand Name: Myfortic
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: S0034
  • Project Status: Complete
  • Submission Type: New

Drug eluting stents: an economic evaluation

Published on: February 25, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Overviews

Technology Name Drug eluting stents Disease or Condition Patients with coronary artery disease commonly undergo balloon angioplasty to unblock narrowed arteries carrying blood to the heart. However, a frequent consequence of the treatment is re-narrowing (restenosis) of a blood vessel that has been opened. Technology Description Bare metal stent...

Tags

Angioplasty, Balloon Angioplasty, Stents, Drug Delivery Systems, Coronary Restenosis, Coronary Disease, Coronary Heart Disease, Cost-Benefit Analysis, Cost Effectiveness, Decision Support Techniques, Coronary Artery Disease, Angioplasty, Balloon, Coronary artery disease, Medical devices, Balloon, Angioplastie, Coronary stenting, Système délivrance médicament, Drug eluting stents, Restenose coronaire, Vaisseaux coronaires, maladies, Analyse coût bénéfice, Systèmes aide décision, Decision analytic model

Economic evaluation of drug eluting stents

Published on: February 25, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Disease or Condition Patients with coronary artery disease commonly undergo balloon angioplasty to unblock narrowed arteries carrying blood to the heart. However, a frequent consequence of the treatment is re-narrowing (restenosis) of a blood vessel that has been opened. Technology Description Bare metal stents (BMS) were introduced in 1994 to r...

Tags

Angioplasty, Balloon Angioplasty, Stents, Drug Delivery Systems, Coronary Restenosis, Coronary Disease, Coronary Heart Disease, Cost-Benefit Analysis, Decision Support Techniques, Coronary Artery Disease, Angioplasty, Balloon, Coronary artery disease, Medical devices, Balloon, Angioplastie, Coronary stenting, Système délivrance médicament, Drug eluting stents, Restenose coronaire, Vaisseaux coronaires, maladies, Analyse coût bénéfice, ost effectiveness, Systèmes aide décision, Decision analytic model

Artificial skin grafts in chronic wound care: a meta-analysis of clinical efficacy and a review of cost-effectiveness

Published on: February 23, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Name Artificial skin grafts to treat chronic skin wounds Disease or Condition Chronic skin ulceration that is caused by various diseases is a major cause of illness and death in adults and elderly people. Although most wounds heal with conventional treatment, some do not, particularly leg ulcers in patients with poor venous blood circ...

Tags

Skin Transplantation, Wounds and Injuries, Skin Ulcer, Meta-Analysis, Diabetic Foot, Varicose Ulcer, Safety, Cost-Benefit Analysis, Cost Effectiveness, Treatment Outcome, Artificial Skin, Wounds and injuries, Transplantation peau, Skin grafts, Artificial skin grafts, Replacement skin, Dermagraft, Apligraf, Plaies et traumatismes, Chronic wounds, Skin ulceration, Méta-analyse, Pied diabétique, Diabetic foot ulcer, Ulcère variqueux, Venous leg ulcer, Sécurité, Analyse coût bénéfice, Évaluation resultants traitement, Clinical outcome

Insulin glargine (rDNA origin) (Lantus)

Last Updated: February 11, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Insulin glargine (rDNA origin)
Indications: Diabetes mellitus, Type 1 & 2

  • Brand Name: Lantus
  • Manufacturer: Aventis Pharma Inc.
  • Project Number: S0033
  • Project Status: Complete
  • Submission Type: New

Annual Report 2003-2004

Published on: February 10, 2005
Result type: Reports
Product Line: Other

Tags

Annual Reports, annual report, rapport annuel, 2003-2004annual report, 2003-2004

Botulinum Toxin A for upper and lower limb spasticity: A systematic review

Published on: February 4, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Name Botulinum toxin A (BTX-A) Disease or Condition Spasticity is a symptom that can cause disability in affected patients. It is characterized by increased muscle tone. Because it may interfere with voluntary movements, it can affect the activities of daily living. Spasticity is treated in an effort to decrease muscle tone, alleviate...

Tags

Review Literature, Botulinum Toxin Type A, Muscle Spasticity, Treatment Outcome, Cerebral Palsy, Multiple Sclerosis, Stroke, Musculoskeletal, Revue de la littérature, systematic review, Toxine botulinique type a, Botulinum toxin a, botox, Spasticité musculaire, spasticity, upper limb spasticity, lower limb spasticity, Évaluation resultants traitement, clinical outcome

Laronidase (Aldurazyme)

Last Updated: February 3, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Laronidase
Indications: Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie

  • Brand Name: Aldurazyme
  • Manufacturer: Genzyme Canada
  • Project Number: S0032
  • Project Status: Complete
  • Submission Type: New

Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: A systematic review of efficacy and safety evidence

Published on: January 31, 2005
Result type: Reports

Technology Name Raloxifene (Evista®) Disease or Condition Osteoporosis is a progressive condition of decreased bone mass. This leads to fragile bones, which are prone to fracture. In women, osteoporotic fractures of the vertebrae can result in back pain, decreased quality of life and an increased risk of spinal fractures. Technology Description ...

Tags

Raloxifene, Evista, Osteoporosis, Postmenopausal Osteoporosis, Spinal Fractures, Osteoporotic Fractures, Primary Prevention, Risk Reduction, Treatment Outcome, Review Literature, Osteoporosis, Postmenopausal, Osteoporosis, Musculoskeletal, Postmenopausal, Ostéoporose postménopause, Fracture vertébrale, vertebral fractures, Prévention primaire, Évaluation resultants traitement, clinical outcome, Revue de la littérature, systematic review